Patents by Inventor Shigeru Miyagawa
Shigeru Miyagawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220249613Abstract: Cell cultures for treating peripheral arterial disease, methods for producing the cell cultures and methods for treating peripheral arterial disease using the cell cultures are provided. The cell cultures may be 100 to 500 ?m in size and may possess an extracellular matrix on an outer surface of the cell culture, and the like are provided.Type: ApplicationFiled: May 2, 2022Publication date: August 11, 2022Applicants: OSAKA UNIVERSITY, TERUMO KABUSHIKI KAISHAInventors: Yoshiki SAWA, Shigeru MIYAGAWA, Keisuke MIYAKE, Kenji OYAMA
-
Publication number: 20220142507Abstract: A heart failure diagnostic device includes a piezoelectric sensor sheet having flexibility and configured to output a detection signal corresponding to an input vibration. A respiratory signal acquisition unit is configured to extract, as a respiratory signal, a signal of a vibration frequency caused by respiration from the detection signal detected by the piezoelectric sensor sheet. A power spectrum calculator is configured to obtain a power spectrum of a respiratory frequency band from the respiratory signal, and a signal corrector is configured to correct the detection signal such that in the power spectrum, a maximum value of a first-order frequency component of a respiratory waveform is not smaller than 1.5 times a maximum value of a second-order frequency component of the respiratory waveform to obtain the respiratory signal.Type: ApplicationFiled: January 26, 2022Publication date: May 12, 2022Inventors: Wataru TAKAHASHI, Masanori YAMAMOTO, Atsuki SHIMIZU, Mitsuyoshi KONDO, Jun Taguchi, Hidetsugu ASANOI, Yoshiki SAWA, Shigeru MIYAGAWA
-
Publication number: 20210388320Abstract: Provided is a cell population comprising differentiated cells obtainable by inducing differentiation of pluripotent stem cells, wherein the content ratio of undifferentiated pluripotent stem cells is 0.2% or less.Type: ApplicationFiled: July 28, 2021Publication date: December 16, 2021Inventors: Shigeo Masuda, Nagako Sougawa, Satsuki Fukushima, Shigeru Miyagawa, Yoshiki Sawa
-
Patent number: 11124770Abstract: A sheet-shaped cell culture is disclosed that includes myocardial cells derived from pluripotent stem cells and has excellent functional properties. A sheet-shaped cell culture obtained by culturing a cell population that includes myocardial cells derived from pluripotent stem cells, wherein the proportion of the number of the myocardial cells derived from pluripotent stem cells to the total number of cells in the cell population is 50% to 70%; a method of producing the sheet-shaped cell culture; a composition including the sheet-shaped cell culture; and a method of treating a disease using the sheet-shaped cell culture or the composition.Type: GrantFiled: May 12, 2017Date of Patent: September 21, 2021Assignees: TERUMO KABUSHIKI KAISHA, OSAKA UNIVERSITYInventors: Hiroko Iseoka, Yoshiki Sawa, Shigeru Miyagawa, Satsuki Fukushima
-
Publication number: 20210187031Abstract: It has been found that a cell cluster obtained by causing just isolated cells to adhere to each other secretes adiponectin after transplantation to the heart, and thereby has an excellent therapeutic effect on heart disease.Type: ApplicationFiled: January 18, 2017Publication date: June 24, 2021Applicant: OSAKA UNIVERSITYInventors: Daisuke KAJITA, Satsuki FUKUSHIMA, Shigeru MIYAGAWA, Yoshiki SAWA
-
Publication number: 20210113464Abstract: The present invention provides a clinically applicable, safe and convenient, pharmaceutical composition for disease site-specific treatment. The pharmaceutical composition for disease site-specific treatment comprises a stealth liposome having a prostaglandin I2 receptor agonist encapsulated therein.Type: ApplicationFiled: November 27, 2017Publication date: April 22, 2021Inventors: Yoshiki Sawa, Shigeru Miyagawa, Yoshiki Sakai, Yasuhiro Yanagi
-
Publication number: 20210009934Abstract: When detachment of a cell sheet from a culture dish has started at an unintended timing, immediately detach the cell sheet from the culture dish while preventing generation of wrinkles and the like in the cell sheet. A cell culture device captures an image of cells in the culture dish, and controls a cooling mechanism and a shaking mechanism based on the image so as to shake the cells while cooling them.Type: ApplicationFiled: March 12, 2019Publication date: January 14, 2021Applicants: DAI NIPPON PRINTING CO., LTD., OSAKA UNIVERSITY, TERUMO KABUSHIKI KAISHAInventors: Taro NAGAI, Yoshiki SAWA, Shigeru MIYAGAWA, Kenji OYAMA
-
Publication number: 20200392466Abstract: Disclosed is a method for producing a high-quality graft from pluripotent stem cell-derived differentiation-induced cells, a graft produced by using the method, and a method for treating a disease using the graft are described Embodiments of a method for producing a graft are described, which include a step of performing an operation for removing undifferentiated cells in a cell population containing pluripotent stem cell-derived differentiation-induced cells, optionally a step of freezing the cell population and thereafter thawing the cell population, and a step of seeding the obtained cell population on a culture substrate and performing graft-forming culture.Type: ApplicationFiled: August 26, 2020Publication date: December 17, 2020Applicants: OSAKA UNIVERSITY, TERUMO KABUSHIKI KAISHAInventors: Yoshiki Sawa, Shigeru Miyagawa, Kenji Oyama, Fumiya Ohashi
-
Publication number: 20200360391Abstract: The present invention provides a pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure. The pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure comprises, as an active ingredient, at least one member selected from the group consisting of protease inhibitors, thromboxane A2 synthase inhibitors, thromboxane A2 synthase antagonists, phosphodiesterase (PDE) inhibitors, tyrosine kinase inhibitors, HMG-CoA reductase inhibitors, and antifibrotic agents. (The pharmaceutical composition includes biodegradable polymer-encapsulated, long-acting preparations thereof.Type: ApplicationFiled: June 1, 2020Publication date: November 19, 2020Applicants: Osaka University, Cardio IncorporatedInventors: Yoshiki Sawa, Shigeru Miyagawa, Yoshiki Sakai, Yasuhiro Yanagi
-
Patent number: 10696948Abstract: The present invention provides a method for preparing a clinically applicable, safe and less damaged cardiomyocyte population through a brief and simple procedure from a cell population obtained by induced differentiation of pluripotent stem cells into cardiomyocytes. The present invention relates to a method for preparing a cardiomyocyte population, the method comprising the steps of: (1) inducing pluripotent stem cells to differentiate into cardiomyocytes, (2) bringing a cell population obtained by the induced differentiation into contact with a laminin selected from the group consisting of laminin ?2?1?1, laminin ?2?2?1, laminin ?1?1?1 and laminin ?1?2?1, or a fragment thereof having integrin binding activity, and (3) retrieving cells adherent to the laminin or the laminin fragment.Type: GrantFiled: September 14, 2015Date of Patent: June 30, 2020Assignee: OSAKA UNIVERSITYInventors: Yukiko Ochi, Kiyotoshi Sekiguchi, Shigeru Miyagawa, Yoshiki Sawa, Antti Markus Siltanen
-
Publication number: 20200171092Abstract: The purpose of the present invention is to provide a therapeutic agent for dilated cardiomyopathy disease which produces excellent effects in the treatment of dilated cardiomyopathy (DCM) and provides a given benefit to a large number of patients. The present invention is a therapeutic agent for dilated cardiomyopathy comprising at least one selected from the group consisting of mesenchymal stem cell and microparticles derived from the mesenchymal stem cell. It is preferable that the mesenchymal stem cell is a cell having the ability to contain or secrete microparticles, that the microparticles have an average particle size of 1000 nm or less, and that they are exosomes.Type: ApplicationFiled: May 8, 2018Publication date: June 4, 2020Applicants: OSAKA UNIVERSITY, ROHTO PHARMACEUTICAL CO., LTD.Inventors: Yoshiki Sawa, Shigeru Miyagawa, Daisuke Kajita, Hayato Kurata, Kotoe Tamada, Hiroyuki Nishida
-
Publication number: 20200109368Abstract: A method for preparing differentiation-induced cells from embryoid bodies derived from pluripotent stem cells is provided. The method includes adding a protease to embryoid bodies. The protease disperses the embryoid bodies, and the protease has an enzyme activity in the range from 0.3 to 4.0 recombinant protease activity unit (rPU)/ml.Type: ApplicationFiled: December 4, 2019Publication date: April 9, 2020Applicants: TERUMO KABUSHIKI KAISHA, OSAKA UNIVERSITYInventors: Hiroko ISEOKA, Fumiya OHASHI, Yoshiki SAWA, Shigeru MIYAGAWA
-
Publication number: 20200102541Abstract: A method for producing a cell culture containing desired cells is provided. The desired cells are induced to be differentiated from pluripotent stem cells. The method includes seeding a cell population by dispersing embryoid bodies obtained by inducing differentiation from the pluripotent stem cells to the desired cells. The embryoid bodies are dispersed at a density reaching confluence or higher.Type: ApplicationFiled: December 4, 2019Publication date: April 2, 2020Applicants: TERUMO KABUSHIKI KAISHA, OSAKA UNIVERSITYInventors: Fumiya OHASHI, Hiroko ISEOKA, Yoshiki SAWA, Shigeru MIYAGAWA
-
Publication number: 20200045955Abstract: This composition can be easily added when cryopreserving cells and improves cell viability. 1 volume % of the composition containing 0.01 wt % to 20 wt % of a sophorose lipid is added just before or up to 6 hours before cryopreservation and cells are stored. This composition can improve cryopreservation cell viability as it reduces freezing damage to cells. With this composition, cells can be stored without using DMSO and blood serum. This is a simple and inexpensive storage method as it does not require fine control of the freezing rate during cell cryopreservation.Type: ApplicationFiled: January 30, 2018Publication date: February 13, 2020Inventors: Asuka Nogami, Motoki Tatsumi, Nanase Ishii, Mizuyuki Ryu, Yoshihiko Hirata, Yoshiki Sawa, Shigeru Miyagawa, Atsuhiro Saito, Hirotatsu Ohkawara
-
Publication number: 20190343924Abstract: The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy.Type: ApplicationFiled: January 26, 2018Publication date: November 14, 2019Inventors: Katsuto TAMAI, Yoshiki SAWA, Shigeru MIYAGAWA, Takashi KIDO, Takasumi GOTO, Takehiko YAMAZAKI
-
Publication number: 20190343841Abstract: The present invention provides a pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure. The pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure comprises, as an active ingredient, at least one member selected from the group consisting of protease inhibitors, thromboxane A2 synthase inhibitors, thromboxane A2 synthase antagonists, phosphodiesterase (PDE) inhibitors, tyrosine kinase inhibitors, HMG-CoA reductase inhibitors, and antifibrotic agents. (The pharmaceutical composition includes biodegradable polymer-encapsulated, long-acting preparations thereof.Type: ApplicationFiled: December 27, 2017Publication date: November 14, 2019Applicants: Osaka University, Cardio IncorporatedInventors: Yoshiki Sawa, Shigeru Miyagawa, Yoshiki Sakai, Yasuhiro Yanagi
-
Publication number: 20190255116Abstract: The present invention addresses the problem of providing a disease-treating agent which exerts an excellent effect in treating diseases requiring an emergency surgery such as heart failure and which is efficacious at a certain level for a large number of patients. The present invention pertains to a kit for preparing a disease-treating agent, said kit comprising a) a fibrinogen solution, b) a thrombin solution and c) mesenchymal stem cells, in separate forms respectively. It is preferred that c) the mesenchymal stem cells are allogeneic to a subject to be treated. Also, the present invention pertains to a kit for preparing a disease-treating agent, said kit being to be used by, when in use, suspending c) the mesenchymal stem cells in either a) the fibrinogen solution or b) the thrombin solution, and then spraying the cell suspension thus obtained directly to a disease site substantially simultaneously with either b) the thrombin solution or a) the fibrinogen solution that is not used in the suspending step.Type: ApplicationFiled: October 13, 2017Publication date: August 22, 2019Applicants: OSAKA UNIVERSITY, ROHTO PHARMACEUTICAL CO., LTD.Inventors: Yoshiki Sawa, Shigeru Miyagawa, Daisuke Kajita, Kotoe Tamada
-
Publication number: 20190153391Abstract: The present invention provides a method for preparing a clinically applicable, safe and less damaged cardiomyocyte population through a brief and simple procedure from a cell population obtained by induced differentiation of pluripotent stem cells into cardiomyocytes. The present invention relates to a method for preparing a cardiomyocyte population, the method comprising the steps of: (1) inducing pluripotent stem cells to differentiate into cardiomyocytes, (2) bringing a cell population obtained by the induced differentiation into contact with a laminin selected from the group consisting of laminin ?2?1?1, laminin ?2?2?1, laminin ?1?1?1 and laminin ?1?2?1, or a fragment thereof having integrin binding activity, and (3) retrieving cells adherent to the laminin or the laminin fragment.Type: ApplicationFiled: September 14, 2015Publication date: May 23, 2019Applicant: OSAKA UNIVERSITYInventors: Yukiko OCHI, Kiyotoshi SEKIGUCHI, Shigeru MIYAGAWA, Yoshiki SAWA, Antti Markus SILTANEN
-
Publication number: 20180153155Abstract: A method is disclosed for cryopreservation of cardiocytes derived from pluripotent stem cells or mesenchymal stem cells derived from adipose tissue or bone marrow, the method maintaining the function of the cardiocytes derived from differentiated pluripotent stem cells or mesenchymal stem cells derived from adipose tissue or bone marrow, and yet reducing the possibility for tumorigenesis of undifferentiated pluripotent stem cells or mesenchymal stem cells derived from adipose tissue or bone marrow. A method is also disclosed for cryopreservation of cardiocytes derived from pluripotent stem cells or mesenchymal stem cells (derived from adipose tissue or bone marrow, the method including dissociating cells from a cell population which has been induced to differentiate into cardiocytes from pluripotent stem cells or mesenchymal stem cells derived from adipose tissue or bone marrow.Type: ApplicationFiled: January 16, 2018Publication date: June 7, 2018Applicants: TERUMO KABUSHIKI KAISHA, OSAKA UNIVERSITYInventors: Fumiya OHASHI, Shigeru MIYAGAWA, Yoshiki SAWA, Shigeo MASUDA, Satsuki FUKUSHIMA, Atsuhiro SAITO
-
Patent number: 9968716Abstract: The present invention provides a drug-eluting stent graft for preventing stent graft-related complications as well as treating aneurysm. Specifically, the present invention relates to a drug-eluting stent graft comprising a drug, a drug-retaining agent and a stent graft, and a method for therapy of aneurysm including the use of the drug-eluting stent graft.Type: GrantFiled: September 10, 2014Date of Patent: May 15, 2018Assignees: ONO PHARMACEUTICAL CO., LTD., OSAKA UNIVERSITYInventors: Yoshiki Sawa, Toru Kuratani, Koichi Toda, Takayoshi Ueno, Shigeru Miyagawa, Satsuki Fukushima, Atsuhiro Saito, Yoshiki Watanabe, Yoshiki Sakai